Investigational Drug Details
| Drug ID: | D153 |
| Drug Name: | Benazepril |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00542 |
| DrugBank Description: | Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836]. |
| PubChem ID: | 5362124 |
| CasNo: | 86541-75-5 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC |
| Structure: |
|
| InChiKey: | XPCFTKFZXHTYIP-PMACEKPBSA-N |
| Molecular Weight: | 424.4895 |
| DrugBank Targets: | Angiotensin-converting enzyme |
| DrugBank MoA: | Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II[FDA Label]. Inhibition of ACE results in decreased plasma angiotensin II[FDA Label]. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion[FDA Label]. |
| DrugBank Pharmacology: | Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by esterases to its active Benazeprilat[A836], is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients[A840,A838,A837]. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals[A840,A836]. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II[FDA Label]. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex[FDA Label]. |
| DrugBank Indication: | Benazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label]. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1370 | NCT01554982 | PHASE3 | COMPLETED | YES | 2012-08 | 2016-07-13 | Details |
| L3170 | NCT06532682 | PHASE4 | ACTIVE_NOT_RECRUITING | NO | 2024-07-01 | 2024-08-01 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details | |
| T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
| T15 | Steryl-sulfatase | STS | INHIBITOR | Hydrolase | P08842 | STS_HUMAN | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|